600 patients66,869 observations120 daysLIVE

Patient P-01833

Synthetic patientNBL-101 · Day 103 · 35–44 · M · baseline S14Open companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
93%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 70 ME-01 recommendedMonitoring Escalation ME-01
  4. Day 71 Patient acceptedStarted ME-01 in the companion
  5. Day 74 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Toxicity-27
  • Inflammatory activity-6
  • Nutritional resilience+6
  • Treatment adherence+6

What helped?

  • Monitoring Escalation ME-01Day 70
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 59
    • WearableHRV 22 ms, trending down
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 43/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 25
    • WearableResting HR 82 bpm
  • Mucosal barrier integrity 20
    • Daily logGI symptom score 69 and rising
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 1.8 · butyrate capacity 43/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
21 ms
Sleep
6.5 h
Steps
6,945
Resting HR
83 bpm
Daily log: GI score 69, nutritional resilience 39, adherence 40.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0169250%S14NP-02improved49
P-0182450%S1442
P-0157649%S14NP-02no change49
P-0187249%S14NP-02improved47
P-0177548%S14SC-12improved48
P-0176047%S1442
P-0186547%S14NP-02no change51
P-0159546%S14GI-04no change51
P-0146245%S14NP-02improved47
P-0148245%S14GI-04improved47
P-0184345%S14SC-12no change45
P-0133244%S14NP-02improved43